Candin Purple Book BLA 103257
- BLA number
- 103257
- Proprietary names
- Candin
- Proper names
- Candida albicans Skin Test Antigen for Cellular Hypersensitivity
- Applicant
- Nielsen Bioscience, Inc
- Center
- CBER
- First observed release
- 2020-08-01
- Latest observed release
- 2026-06-01
- Newest archive release
- 2026-06-01
- FDA patent list
- No patents listed in the captured FDA patent list; source updated 2025-06-11
- Coverage
- Present in newest release
Latest Known Product Presentations#
Product, Proprietary name, Proper name table| Product | Proprietary name | Proper name | License type | Strength | Dosage form | Route | Presentation | Marketing | Licensure | Approval | Patent list provided |
|---|
| 001 | Candin | Candida albicans Skin Test Antigen for Cellular Hypersensitivity | 351(a) | 1U/.1ML | Injection | Intradermal | Multi-Dose Vial | Rx | Licensed | 1995-11-27 | |
Published Patent List#
No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events#
Release, Event, Product table| Release | Event | Product | Name | License type | Status | Applicant |
|---|
| 2021-08-01 | U | 001 | Candin | 351(a) | Rx | Nielsen Bioscience, Inc |
| 2021-05-01 | U | 001 | Candin | 351(a) | Rx | Nielsen Bioscience, Inc |
| 2020-08-01 | R | 001 | Candin | 351(a) | Rx | Nielsen Bioscience, Inc |
Observed Product State History#
Release, Product, Name table| Release | Product | Name | License type | Marketing | Licensure | Approval |
|---|
| 2020-08-01 | 001 | Candin | 351(a) | Rx | Licensed | 1995-11-27 |